MDR baseline reporting should be implemented on pilot basis, if at all, HIMA tells FDA.
This article was originally published in The Gray Sheet
Executive Summary
MANUFACTURER MDR BASELINE REPORTING REQUIREMENTS should be implemented on a pilot basis, if at all, the Health Industry Manufacturers Association says in Jan. 10 comments on FDA's final rule for device manufacturer and user facility reporting ("The Gray Sheet" Dec. 11, p. 3). HIMA categorically opposes baseline reporting but says that if FDA insists on implementing the requirement, the reporting "should be initiated as a pilot program for a limited number of devices," such as "the top ten devices in terms of number" of medical device adverse event reports "filed with FDA annually."
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.